Leerink Partnrs Lifts Earnings Estimates for Galapagos

Galapagos NV (NASDAQ:GLPG) – Equities researchers at Leerink Partnrs increased their FY2024 EPS estimates for Galapagos in a report issued on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will earn ($0.47) per share for the year, up from their prior estimate of ($0.48). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Galapagos’ current full-year earnings is $0.52 per share. Leerink Partnrs also issued estimates for Galapagos’ Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.80) EPS and FY2026 earnings at ($1.72) EPS.

Several other analysts have also recently commented on GLPG. Kepler Capital Markets cut shares of Galapagos from a “hold” rating to a “reduce” rating in a report on Wednesday, November 20th. Royal Bank of Canada decreased their target price on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating for the company in a research note on Friday, November 1st. Finally, Leerink Partners assumed coverage on shares of Galapagos in a research note on Monday, September 9th. They issued a “market perform” rating and a $24.00 price target on the stock. Two analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.75.

Galapagos Trading Up 1.6 %

Shares of GLPG stock opened at $27.21 on Wednesday. Galapagos has a 1-year low of $24.16 and a 1-year high of $42.46. The stock’s fifty day simple moving average is $28.10 and its 200-day simple moving average is $27.39.

Institutional Trading of Galapagos

A number of institutional investors have recently added to or reduced their stakes in GLPG. Primecap Management Co. CA raised its holdings in shares of Galapagos by 0.7% during the 2nd quarter. Primecap Management Co. CA now owns 720,240 shares of the biotechnology company’s stock valued at $17,848,000 after purchasing an additional 5,000 shares in the last quarter. Finepoint Capital LP raised its holdings in Galapagos by 2.8% during the third quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company’s stock valued at $16,058,000 after buying an additional 15,000 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in Galapagos by 23.2% during the second quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company’s stock valued at $12,018,000 after buying an additional 91,366 shares in the last quarter. Millennium Management LLC lifted its position in shares of Galapagos by 5.3% in the second quarter. Millennium Management LLC now owns 341,639 shares of the biotechnology company’s stock worth $8,466,000 after buying an additional 17,089 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Galapagos by 1.6% during the 2nd quarter. Renaissance Technologies LLC now owns 270,800 shares of the biotechnology company’s stock worth $6,710,000 after acquiring an additional 4,300 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.